Inositec AG
Pharmaceuticals - Zurich, Zurich, Switzerland
Inositec AG Employees
Inositec AG Details
Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable InosituneTM technology to adjust the chemical and physical properties of inositol phosphate (IP6) analogs, Inositec is developing a novel class of drugs currently focusing on high-unmet medical needs related to calcification disorders. The lead compound INS-3001 is a cardiovascular calcification inhibitor in development for aortic valve stenosis. Inositec was founded in December 2015 based on the award-winning research of Dr. Mattias Ivarsson, Prof. Jean-Christophe Leroux and Prof. Bastien Castagner at ETH Zurich, Switzerland. Inositec was acquired by Vifor Pharma in 2021.
Inositec AG Technologies
Email Providers
Outlook
CMS
WordPress.org
Hosting
GoDaddy Hosting
Other
Google Maps (Non Paid Users)
Analytics and Tracking
Google Analytics